- Home
- JUNS vs ABVC Comparison
JUNS vs ABVC Comparison
Compare JUNS & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- ABVC
- Stock Information
- Founded
- JUNS 2015
- ABVC 2015
- Country
- JUNS United States
- ABVC United States
- Employees
- JUNS N/A
- ABVC N/A
- Industry
- JUNS
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- ABVC Health Care
- Exchange
- JUNS NYSE
- ABVC Nasdaq
- Market Cap
- JUNS 20.5M
- ABVC 22.1M
- IPO Year
- JUNS 2024
- ABVC N/A
- Fundamental
- Price
- JUNS $1.11
- ABVC $1.84
- Analyst Decision
- JUNS
- ABVC
- Analyst Count
- JUNS 0
- ABVC 0
- Target Price
- JUNS N/A
- ABVC N/A
- AVG Volume (30 Days)
- JUNS 723.0K
- ABVC 316.0K
- Earning Date
- JUNS 08-11-2025
- ABVC 08-13-2025
- Dividend Yield
- JUNS N/A
- ABVC N/A
- EPS Growth
- JUNS N/A
- ABVC N/A
- EPS
- JUNS N/A
- ABVC N/A
- Revenue
- JUNS N/A
- ABVC $508,383.00
- Revenue This Year
- JUNS N/A
- ABVC $735.18
- Revenue Next Year
- JUNS N/A
- ABVC N/A
- P/E Ratio
- JUNS N/A
- ABVC N/A
- Revenue Growth
- JUNS N/A
- ABVC 1904.43
- 52 Week Low
- JUNS $0.51
- ABVC $0.40
- 52 Week High
- JUNS $19.51
- ABVC $2.25
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- ABVC 61.24
- Support Level
- JUNS N/A
- ABVC $1.58
- Resistance Level
- JUNS N/A
- ABVC $2.25
- Average True Range (ATR)
- JUNS 0.00
- ABVC 0.17
- MACD
- JUNS 0.00
- ABVC 0.02
- Stochastic Oscillator
- JUNS 0.00
- ABVC 52.87
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.